u/first_hundred

Do you have the publication or the press release?

How long was the randomised phase before any extension?

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

retention time alone is not identity

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.

Left up and flaired Explainer. This is the answer we keep linking, written properly.

a press release is not a publication

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Sent one vial to Janoshik and Medutest. 97.1% and a claimed 97.0%. Cost me more than the vial and I would do it again.

area percent is relative to what the detector saw and nothing else

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

area percent is relative to what the detector saw and nothing else

The analytical point, which this board keeps getting wrong by importing habits from the peptide side.

For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.

So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.

a non-peptide agonist does not degrade the way a peptide does

a mean is not a promise

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Removed — cropped document. Post the whole page or do not post it; the fields people crop are the fields that matter.

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.

That is area percent, not mass percent. The trace cannot give you the second one.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Does the lot on the vial match the lot on the page?

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Did you get the chromatogram or only the summary line?

Removed — cropped document.

This is the sentence to take away. The rest of the thread is footnotes to it.

The four things a certificate must carry, and what each one is for.

Batch identifier ties the document to your vial; without it the document is about somebody else’s material. Date of analysis tells you when the number was true. Method — column, gradient, wavelength — is what makes the figure reproducible rather than asserted. Individual related substances give you the shape of what else is in there.

Everything beyond those four is welcome. Anything missing from them is a question to ask before you order, and in my experience the answer arrives quickly from the suppliers who have a batch record to draw it from.

net peptide content and purity are two different numbers on the same vial

Small fix — 214nm, not 280nm. It matters here because the impurity you are asking about barely absorbs at the longer wavelength.

Which trial, and which arm?

Correction: SURMOUNT is the obesity programme and SURPASS is the diabetes one. The figure you quoted belongs to the other one.

Net peptide content is the fraction of the powder that is actually peptide once counterion, water and residual solvent are accounted for. A 99% pure acetate salt can still be about 85% peptide by mass.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

Your name and address edited out of the screenshot above. The batch details are untouched and should stay.

Agreed. Half the arguments on this site are two people quoting different trials at each other without noticing.

Your name and address edited out of the screenshot above. The batch details are untouched and should stay.

Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.

What was the comparator?

SURPASS is the diabetes programme and reports glycaemic endpoints

Read a press release and the publication three months apart. The hedging in the second one was substantial.